The Latest Articles from Streetwise Reports


Translate Bio Shares Rise 29% on Sanofi's $3.2 Billion Buyout Bid

  ()
Shares of Translate Bio Inc. soared to a new 52-week high after the company reported it agreed to be acquired by its collaborative partner Sanofi SA for $38 per share in cash in a deal valued at $3.2 billion. read more >

Gene Editing May Terminate Virus Transmission, Combat Heart and Brain Disease With a Single Shot

Contributed Research
  ()
McAlinden Research Partners explores the acceleration of gene-editing technology and notes the market is poised to expand as the World Health Organization (WHO) creates new standards for companies to follow. read more >

Annovis Shares Rise on Positive Phase 2 Alzheimer's and Parkinson's Disease Trial Results

  ()
Shares of Annovis Bio Inc. traded 20% higher after the company reported positive interim data from its Phase 2 clinical studies of ANVS401 (Posiphen) for treatment of Alzheimer's and Parkinson's diseases. read more >

Sorrento Therapeutics Proceeds with COVID-19 Drug Treatment Trial

Research Report
  ()
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report. read more >

Biopharma Creates New Business Unit Ahead of Commercial Product Launch

Research Report
  ()
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report. read more >

Rritual Superfoods at Full-Throttle, Adding CVS, Amazon Along the US Distribution Superhighway

Contributed Opinion
  ()
Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution. read more >

Tilray Shares Fly High on Strong Q4 and FY Revenue Growth

  ()
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition. read more >
News Update

Rapidly Growing Virtual Healthcare Firm Adds Three New US Group Medical Practice Clients

News Update
  ()
Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform. read more >

Coverage Initiated on Company with a 'Genuine Physiological Heart Replacement Therapy'

Research Report
  ()
The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report. read more >

Biopharma Partners with NIH to Advance Women's Hormone-Free Contraceptive

Research Report
  ()
A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience. read more >

Cannabis Market Delivering for Consumers and Investors

  ()
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. read more >

Small Bio-tech Gets $17.7 Million Backing from U.S. Department of Defense to Treat SARS-CoV-2 Delta Variant

  ()
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets. read more >

HCA Healthcare Shares Gain 15% on Strong Q2 Performance and Raised FY Outlook

  ()
HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21. read more >

Cytokinetics Shares Rise 41% on Positive Phase 2 Redwood-HCM Trial Data

  ()
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial. read more >

Zynex Shares Rise as Firm Notches Significant Q2 Order Growth and Raises EBITDA Outlook

  ()
Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million. read more >

Merger of Two Biopharmas 'Brings a New Dawn'

Research Report
  ()
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report. read more >

FDA, EMA Approve Drug Firm's Phase 3 Liver Cancer Trial Design

Research Report
  ()
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report. read more >

US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform

Contributed Research
  ()
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when." read more >

Alphatec Shares Rise After Firm Announces Strong Organic Revenue Growth in Q2

  ()
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue. read more >

Pharma Company Working to Unlock Psychedelic Drug's Potential for Stroke Recovery

  ()
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke. read more >

Biopharma Files New Drug Application for Lead Clinical Product

Research Report
  ()
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a ROTH Capital Partners report. read more >

Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity

Research Report
  ()
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report. read more >

Biohaven Posts Revenue of $93 Million in Q2 for Its Migraine Medicine

  ()
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment. read more >

ALX Oncology Shares Rise on Positive Response and Survival Data in Phase 1b Gastric Cancer Trial

  ()
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer. read more >

Alector Partners with GSK to Develop Monoclonal Antibodies for Neurodegenerative Diseases

  ()
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's. read more >
Showing Results: 1 to 25 of 137 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts